TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,900,000 shares, a decline of 14.8% from the February 28th total of 2,230,000 shares. Based on an average trading volume of 433,800 shares, the short-interest ratio is presently 4.4 days. Approximately 4.4% of the company's stock are short sold.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new stake in TScan Therapeutics in the 4th quarter valued at $32,000. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics in the 4th quarter worth about $32,000. ProShare Advisors LLC acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth about $40,000. Wells Fargo & Company MN lifted its holdings in TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in TScan Therapeutics in the fourth quarter valued at about $59,000. 82.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Morgan Stanley restated an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. Needham & Company LLC reduced their price target on TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Thursday, March 6th. Barclays dropped their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $9.33.

TScan Therapeutics Stock Performance

TScan Therapeutics stock traded down $0.11 during trading hours on Friday, hitting $1.10. The stock had a trading volume of 601,934 shares, compared to its average volume of 339,547. The company has a 50-day moving average of $1.92 and a two-hundred day moving average of $3.42. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $9.69. The company has a market cap of $62.25 million, a PE ratio of -1.04 and a beta of 1.09.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The firm had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, equities research analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.